FY2026 · ended Jun 30, 2026 · Revenue $51,992 · Filed Oct 13, 2026
Lunai Bioworks Inc. (LNAI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $51,992 and a net loss of $3.6 million. Free cash flow was -$5.3 million. As of Jun 30, 2026 it held $1.7 million in cash and investments and $350,035 in total debt.
Revenue
$51,992
Net income
$-3.56M
+98.0% vs prior year
Operating cash flow
$-5.29M
+32.8% vs prior year
Free cash flow
$-5.29M
+52.1% vs prior year
EPS
$-1.06
+98.8% vs prior year
Dividend per share
None
Shares outstanding
5.03M
-97.8% vs prior year
Net cash
$1.36M
FY 2026
Operating margin
-16729.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LNAI (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Suite 906 Los Angeles, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1527728
- Former names
- RENOVARO INC. (until Aug 26, 2025); RENOVARO BIOSCIENCES INC. (until Feb 7, 2024); Enochian Biosciences Inc (until Aug 1, 2023); DanDrit Biotech USA, Inc. (until Feb 23, 2018); Putnam Hills Corp. (until Feb 11, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $51,992 | — | — | — | — |
| Operating income | -$8.7M | -$189.0M | -$81.6M | -$38.6M | -$116.1M |
| Net income | -$3.6M | -$178.0M | -$88.4M | -$39.7M | -$113.4M |
| Diluted EPS | -$1.06 | -$86.27 | -$0.91 | -$0.71 | — |
| Operating cash flow | -$5.3M | -$7.9M | -$11.0M | -$11.8M | -$15.7M |
| Free cash flow | -$5.3M | — | -$11.0M | -$11.8M | -$15.7M |
| Total assets | $9.9M | $8.2M | $163.1M | $58.3M | $84.6M |
| Total liabilities | $19.0M | $29.6M | $31.2M | $11.8M | $12.0M |
| Stockholders' equity | -$9.0M | -$21.3M | $132.0M | $46.5M | $72.6M |
| Cash and investments | $1.7M | $92,700 | $220,467 | $1.9M | $9.2M |
| Total debt | $350,035 | $737,594 | $1.3M | $969,009 | $1.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice, Officer or director change, Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 16, 2026 |
| 10-K | Annual report | Oct 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Other events
|
Jun 17, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Other events
|
Jun 16, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Other events
|
May 20, 2026 | May 20, 2026 |
All 599 Lunai Bioworks Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.